Background: Deep venous thrombosis (DVT) is increasingly being managed in the outpatient setting, particularly patients deemed low-risk at presentation. The long-term outcomes of these patients remain unclear. Aim: To determine the long-term outcomes of patients with DVT and those with raised D-dimer without DVT managed exclusively by an ambulatory care pathway. Design: Retrospective cohort analysis. Methods: 828 consecutive patients assessed at the Ambulatory Care Clinic of a tertiary care university hospital between 1 January and 31 December 2008 for potential lower limb DVT were analysed. Primary and secondary outcome was all-cause mortality and new diagnosis of cancer, respectively. Median follow-up was 6.4 years. Results: The final cohort comprised 131 patients with DVT, 396 with raised D-dimer without DVT and 165 with normal D-dimer without DVT. Long-term survival was 72.5% for DVT, 75.3% for elevated D-dimer without thrombosis and 93.3% for those with normal D-dimer (P < 0.0001). The risk of death with DVT remained significant after adjusting for age, gender, previous cancer, recent surgery and previous thromboembolism (HR 2.17, 95% CI [1.07, 4.38]). Cancer accounted for 44.4 and 37.8% of deaths within the first and second groups, respectively. 50% of cancers in the former group were diagnosed during follow-up vs. 95.1% in the latter.
Introduction
Venous thromboembolism (VTE) related deaths in the EU are estimated at 370 012 annually, exceeding the number of deaths from lung cancer (353 000), colorectal cancer (215 000) and breast cancer (131 000). 1 In the UK alone, 25 000 deaths annually 2 are attributed to VTE. The long-term survival after an episode of VTE is poor, [3] [4] [5] with mortality risks remaining high even at 10 years after diagnosis. 4 However, most studies on longterm outcomes include hospital in-patients with Deep venous thrombosis (DVT). DVT diagnosed during hospital confinement has been associated with poor survival. 3 The management of DVT in the last decade has changed considerably. Increasingly, DVT is managed in the outpatient or ambulatory care setting. 6, 7 The impetus was the advent of lowmolecular-weight heparins, which negate the need for intravenous unfractionated heparin as a bridge to warfarin. In many institutions, the protocol for outpatient or ambulatory management of potential DVT comprises three key components: diagnostic algorithms, risk stratification and treatment pathways for those with confirmed DVT. Here, risk stratification strategies identifies patients at low risk of immediate adverse events who are thus suitable to be managed on an outpatient basis. 8 Outpatient care satisfies cost benefit analysis and is more convenient for patients. 9, 10 However, there are two important questions still to be addressed. First, the long-term outcomes of patients with DVT in this outpatient population are unclear. Typically, these patients are younger, with fewer comorbidities.
11 Second, patients with elevated D-dimer levels but without radiological evidence of DVT receive far less emphasis in most protocols and studies. Thus, their outcomes remain unknown. In this study, we sought to determine the longterm outcomes of these patients who had been managed exclusively by an ambulatory care pathway.
Materials and methods

Study population
We analysed 828 consecutive patients who attended the Ambulatory Care Clinic at the Royal Infirmary of Edinburgh for investigation of potential lower limb DVT between 1 January and 31 December 2008. The Royal Infirmary of Edinburgh serves as a tertiary referral university hospital for Lothian, as well as a local hospital for Edinburgh (population 800 000). The Ambulatory Care Clinic streamlines investigations of potential VTE and manages the treatment after diagnosis. The local ambulatory DVT protocol includes risk stratification to determine suitability for outpatient management. It recommends hospital admission for patients with: adverse social circumstances, significant comorbidities requiring in-patient management, renal failure with creatinine clearance of <30 ml/min, increased risk of bleeding, or severe pain with extensive swelling and discolouration suggestive of phlegmasia cerulean dolens. Patients were divided into three groups: patients with DVT, patients with raised D-dimer without DVT and patients with normal concentration of D-dimer without DVT. Patients who did not reside within Edinburgh postcodes (no follow-up data) or with incomplete clinical data were excluded from analyses (n ¼ 136). Of these, 99 had insufficient data to allow classification into the study groups. The remaining 37 patients were without follow-up data from ISD Scotland, resulting in an attrition of 3.7, 5.9 and 4.1% from each group, respectively. For patients with multiple presentations (n ¼ 63) during the study period, the first presentation was considered as the reference for follow-up.
Outcomes and follow-up
Primary outcomes measured were: all-cause mortality and mortality amenable to healthcare. Causes of mortality considered amenable to health care were defined according to Nolte and McKee (2008) and Tobias and Yeh (2009) 12,13 as deaths from preventable causes (incidence reduction) as well as those that can be treated (case fatality reduction). Secondary outcome was the diagnosis of a new primary cancer during the follow-up period. All cases were followed up from the date of index presentation until the date of death or the 26 November 2014, whichever was earlier.
Data extraction and linkage
Demographic and imaging data were obtained from the electronic integrated clinical records system (TrakCare, InterSystems Corp, MA, USA). The Electronic Data Research and Innovation Service team of the Information Services Division (ISD) from NHS Scotland provided linked national dataset information on mortality (National Records Scotland database), cancer (SMR06), previous DVT (ICD9 451.1 and ICD10 I26, I80.1, I80.2 from Scottish hospitals general inpatient and day case datasets [SMR01]), previous surgery (SMR01) and pregnancy (maternity inpatient and day case datasets [SMR02]). Cancers (excluding non-melanomatous skin cancers) were classified as a previous cancer if the diagnosis was made within five years prior to the index presentation.
We were unable to retrieve data on obesity, thrombophilic disorders, smoking history or use of oestrogen modulators at the time of diagnosis.
Ethical approval
This study received approval from the Caldicott Guardian of NHS Lothian and the Caldicott Guardian of ISD for NHS Scotland.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics for Macintosh, Version 21.0. (IBM Corp., Armonk, NY, USA). Data were presented as mean (SD) for continuous variables and as frequencies and percentages for categorical variables. KaplanMeier survival analysis was used to calculate the cumulative incidence of primary and secondary outcomes. Cox regression models were fitted to adjust for effects of the baseline characteristics and to determine their significance as a predictor for each outcome. The risk of the outcomes was presented as hazard ratios (HRs) (95% confidence intervals). The proportional hazard assumptions were determined using log minus log plots for each variable. A P value of < 0.05 was deemed significant.
Results
Clinical characteristics
The final study cohort comprised 692 patients investigated for potential DVT. Of these, 131 patients (18.9%) had DVT confirmed on venous Doppler ultrasound, 396 (57.2%) had raised D-dimer without DVT and the remaining 165 (23.8%) had normal Ddimer concentrations. Clinical characteristics of the study population are summarized in Table 1 . Among patients with DVT, 115 (87.8%) had thrombus involving the popliteal or more proximal veins.
Survival
The 692 patients were followed up for a median of 6.4 years, representing a total follow-up period of 3884.0 person-years, during which there were 145 deaths (21%). The survival at the end of the follow-up period was 72.5% for the DVT group, 75.3% for the elevated D-dimer without thrombosis group and 93.3% for those with normal D-dimer without DVT ( Table 2 ). The survival for young patients aged < 50 years with DVT remained reduced at 87.5% at the end of the study, compared with 98.7% for those of corresponding age but with a normal D-dimer and no DVT. As shown in Figure 1 , Kaplan-Meier survival curves from index presentation demonstrate a long-term increase in hazards among patients with DVT compared with those with normal D-dimer and no DVT (log ranks P < 0.0001). The survival of patients with DVT was comparable to that of patients with raised D-dimer without DVT (log ranks P ¼ 0.39).
As shown in Table 1 , patients with raised D-dimer without DVT were older than the comparison groups (P < 0.0001). Indeed, the excess risk of death with raised D-dimer remains slightly elevated but is rendered insignificant when adjusting for age, with the HR declining from 4. 
Covariate analyses
Age was an independent risk factor for death across all groups, with a six percent rise in mortality with each advancing year (Table 3) . Other independent risk factors present at diagnosis were male sex, previous diagnosis of cancer and recent surgery. When each study group was considered separately, the most relevant predictors of late death for DVT were age (HR 
Cause of death
Cancer was the leading cause of death among patients with DVT (44.4%), as well as in those with raised D-dimer without DVT (37.8%). Among those with DVT, 50.0% of cancers were diagnosed prior to the index presentation. In contrast, 95.1% of cancers in the raised D-dimer without DVT group were diagnosed during the follow-up period. The types of cancer recorded at the time of death are presented in Table 4 . Cardiovascular diseases (ischaemic heart disease, stroke, ischaemic bowel, peripheral vascular disease or aortic aneurysm) were the underlying cause of death in 25.0% and 30.6% of patients with DVT and those with raised D-dimer without DVT, respectively. VTErelated death was recorded in one case. Underlying causes amenable to healthcare were found in 11.0 and 10.0% of deaths in the DVT and raised D-dimer without DVT groups, respectively. 
New primary cancer
Discussion
With a few exceptions, most patients with DVT are now managed in the outpatient ambulatory care setting. This study addressed important questions regarding the long-term outcomes of these patients. Intuitively, the outcomes are expected to be favourable; patients selected for outpatient management are deemed low-risk at presentation. Furthermore, this study excluded patients who were hospitalized, which has been shown to be associated with a negative impact on survival. Yet our data suggest that the long-term survival of those with DVT managed exclusively in an ambulatory setting is poor with 5-year survival of 74%. Alarmingly, the excess risk of death was significant even among those who were relatively young. In part, this might be explained by the outpatient case selection and the risk stratification strategy employed. The strategy was geared towards identifying whether hospitalization was necessary for the ongoing management of the DVT. The emphasis was on the immediate risk and not the long-term adverse outcomes. This is reflected by the favourable 30-day survival rate in this cohort.
Among the prevailing risk factors, cancer was a strong predictor of poor survival. The relationship between cancer and DVT is well known. Active or previous cancer is a risk factor for DVT and conversely, there is increased risk of being diagnosed with a new primary cancer after an episode of VTE. [15] [16] [17] In this cohort, cancer was the leading cause of death in patients with DVT, and cancer diagnosed prior to DVT was the strongest predictor of death in this group. The risk of late death was 7-fold higher than those without any history of cancer. There was no significant association found between the incidence of new primary cancer and DVT. The possible reasons are 2-fold. First, the sample size is smaller than previous population-based studies. 15, 16 Second, the comparison group of patients with normal D-dimer without DVT are not representative of the general population. In this cohort, DVT per se was associated with a risk of death independent of other risk factors including cancer. Further, the unadjusted survival among patients with raised D-dimer was poor with or without DVT. Some of this might represent unaccounted residual confounders not ascertained in our study which are known to be independent predictors of poor survival -such as cigarette smoking and congestive heart failure. However, a portion of this risk may reflect processes of inherent oxidative stress leading to the activation of inflammatory and coagulation cascades, which are postulated to be the linking mechanism between VTE and atherosclerosis, 18, 19 as well as cancer. 20, 21 It is plausible that these reasons underlie the significant prevalence of cancer and arterial disease observed at the time of death. These same processes are also postulated to be the underpinning reason for the association between D-dimer and mortality. 22, 23 It is already known that raised D-dimer in cancer reflects increased activation of coagulation cascades and is predictive of advanced disease with poor outcomes. [24] [25] [26] Although excess mortality among those with raised D-dimer without DVT is rendered insignificant after adjusting for age, the trend (particularly with the unadjusted survival of 87.1% in those <52 years of age) remains clinically relevant. Current practice often sees this group of patients overlooked in a setting heavily focused on the exclusion of DVT.
Conclusion
In summary, the 5-year survival of DVT in non-hospitalized patients managed exclusively in the outpatient setting is worse than expected. The high prevalence of death due to cancer, ischaemic heart disease and stroke suggests that DVT may be a marker of underlying endothelial perturbation leading to complex interplay between enhanced coagulation and antifibrinolysis. This process may not be addressed by current approaches to anticoagulation. Emphasis should be focused on underlying disease prevention. This is important given that some of the underlying causes of death are amenable to healthcare. Our data support the urgent need for a robust risk stratification algorithm capable of predicting adverse long-term outcomes for both patients with DVT, as well as those with raised D-dimer in the absence of thrombosis. A prospective study is needed to characterize these risk factors and to determine the optimal follow-up.
